HOME >> MEDICINE >> NEWS
Different type of iron supplement is better at boosting iron levels

Fortifying cereals with a different type of iron supplement reduces anaemia, iron-deficiency anaemia and general iron deficiency children in developing countries, and boosts three major iron status indicators, conclude authors of an Article published in this weeks edition of The Lancet.

Sodium Iron EDTA (NaFeEDTA) was found to be much more effective than electrolytic iron, despite the electrolytic form being the most frequently used iron supplement in flour.

Pauline Andango, Kenya Medical Research Institute, Centre for Public Health Research, Nairobi, Kenya and Netherlands-based colleagues studied 516 children aged three to eight years from four schools in Marafa, Kenya, some 10% of whom were suffering from anaemia.

Anaemia is defined as a shortage of red blood cells and/or haemoglobin (the oxygen-carrying iron complex) in the blood one cause of which is iron deficiency.

The authors say: "Fortification of staple cereal flours could be a cost-effective, sustainable way to improve iron status in developing countries."

The children in the study were divided into four groups and each given the same amount of porridge daily, five times a week. The placebo group had porridge made with unfortified whole maize flour. For the other three groups the porridge was fortified with either high-dose NaFeEDTA (56mg/kg), low-dose NaFeEDTA (28mg/kg) or electrolytic iron (56mg/kg).

The researchers found that, compared to the placebo group, the prevalence of iron-deficiency anaemia dropped by 89% for the high-dose NaFeEDTA group, and by 48% for the low-dose NaFeEDTA group, but there was no evidence for any reduction in the electrolytic iron group.

High-dose NaFeEDTA fortified flour also improved three major iron status indicators in the children taking flour fortified with it haemoglobin and plasma ferritin concentrations, and amounts of plasma soluble transferrin receptor. Low-dose NaFeEDTA also improved these
'"/>

Contact: Pauline Andango
pauline.andango@wur.nl
31-620-815-357
Lancet
24-May-2007


Page: 1 2

Related medicine news :

1. Different gene-expression predictors of breast cancer agree, UNC study shows
2. Different options produce similar results
3. Different forms of amyloid beta in Alzheimers disease harm neurons in different ways
4. Different consultants mean different lengths of stay in hospitals
5. Differential heart-attack risks among blacks, whites remain mystery
6. Different antipsychotic medications may have different effects on brain volume
7. Sucampo Pharmaceuticals submits supplemental new drug application for Lubiprostone to treat IBS-C
8. Folic acid supplements do not appear to reduce risk of colorectal tumors
9. Folic acid supplementation lowers stroke risk
10. Some vitamin supplements dont protect against lung cancer
11. Vitamin D supplements may offer cheap and effective immune system boost against TB

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Different type iron supplement better boosting iron levels

(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: